Toxic epidermal necrolysis syndrome induced by tigecycline: a case report.
Alleles
Bacterial Infections
/ drug therapy
Biopsy
Cytochrome P-450 CYP2C19
/ genetics
Glucocorticoids
/ administration & dosage
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunoglobulins, Intravenous
/ administration & dosage
Lymphoma, Large B-Cell, Diffuse
/ immunology
Male
Middle Aged
Skin
/ drug effects
Stevens-Johnson Syndrome
/ diagnosis
Tigecycline
/ adverse effects
Transplantation, Autologous
/ adverse effects
Treatment Outcome
Adverse event
CYP2C19
Stevens–Johnson syndrome
skin rash
tigecycline
toxic epidermal necrolysis
Journal
The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
9
3
2021
Statut:
ppublish
Résumé
A 56-year-old man diagnosed with non-Hodgkin's lymphoma underwent autologous bone marrow transplantation. He was subsequently admitted to the hospital with fever, and his symptoms were initially controlled by multiple antibiotics, including tigecycline. He then developed a generalized body rash that improved after treatment with anti-allergy drugs and steroids. Furthermore, tigecycline treatment for a second time resulted in a severe skin reaction with systemic symptoms, suggesting toxic epidermal necrolysis syndrome (TEN). The patient was shown to have the slow-metabolizing cytochrome P450 2C19 allele, denoted CYP2C19*2. He was transferred to a laminar flow ward and given strict mucosal care, together with corticosteroids and intravenous immunoglobulin. He recovered after 3 weeks of treatment. Tigecycline-induced Stevens-Johnson syndrome (SJS)/TEN has rarely been reported in the Chinese population. However, our experience suggests that Asians are more likely to have adverse reactions to drugs metabolized by the cytochrome P450 enzyme. Early identification of drug reactions and immediate cessation of the suspected drug is essential. Additionally, a combined therapy scheme and a clean laminar flow environment may improve the cure rate of SJS/TEN.
Identifiants
pubmed: 32400243
doi: 10.1177/0300060520922416
pmc: PMC7223212
doi:
Substances chimiques
Glucocorticoids
0
Immunoglobulins, Intravenous
0
Tigecycline
70JE2N95KR
CYP2C19 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
300060520922416Références
Clin Pharmacol Ther. 2010 Jul;88(1):60-8
pubmed: 20375998
Asia Pac Allergy. 2015 Apr;5(2):68-77
pubmed: 25938071
Clin Infect Dis. 2014 May;58(10):1377-85
pubmed: 24599767
Pharmgenomics Pers Med. 2017 May 17;10:183-186
pubmed: 28553132
Clin Pharmacol Ther. 2014 Nov;96(5):542-8
pubmed: 25099164
Arch Dermatol. 1993 Jan;129(1):92-6
pubmed: 8420497
J Am Acad Dermatol. 2013 Aug;69(2):187.e1-16; quiz 203-4
pubmed: 23866879
Biol Pharm Bull. 2012;35(6):967-70
pubmed: 22687540
J Invest Dermatol. 2000 Aug;115(2):149-53
pubmed: 10951229
Expert Opin Pharmacother. 2009 May;10(7):1213-22
pubmed: 19405794
J Antimicrob Chemother. 2005 Oct;56(4):611-4
pubmed: 16120626
JAMA. 2014 Aug 6;312(5):525-34
pubmed: 25096692
Antimicrob Agents Chemother. 2002 Oct;46(10):3164-7
pubmed: 12234839
Ann Pharmacother. 2007 Jun;41(6):965-72
pubmed: 17519296